Novartis Access: Medicines to treat chronic diseases in lower-income countries

Novartis recently announced the launch of the Novartis Access Portfolio, a first-of-its-kind portfolio approach in healthcare industry, aiming to increase availability and affordability of 15 medicines against cardiovascular diseases, diabetes, respiratory illnesses and breast cancer in low and middle income countries.

Videos from this campaign

Content from this campaign

Health & Healthcare

Report Calls for Better Measurement of Access-to-Medicine Programs to Support the World’s Poorest
Pharmaceutical companies have long experience in measuring the impact of their business programs. The same should apply to their access-to-medicine efforts. Richard Laing, from the Boston University (BU) School of Public Health and former World Health Organization official, says that many efforts to expand access to medicines fail to gather sufficient evidence on how effective they are.

Health & Healthcare

Novartis Access and Government of Pakistan Sign Memorandum of Understanding
Novartis reaches agreement with Pakistan to supply medicines that address the rapid rise of chronic illness among poor people in the world's sixth most populous nation. Novartis Access medicines will be made available to the poorest population in Pakistan through hospitals under the Prime Minister’s National Health Insurance Program.

Health & Healthcare

The Key to Fighting Chronic Disease in South-East Asia: Young People
The ASEAN region has 630 million people – and more than half are under age 30. Harald Nusser, Head of Novartis Social Business says that to fight the rise of chronic disease in South East Asia, we need to explore new ways to help youth there be better informed about diagnosis, treatment and about the importance of healthy lifestyles.

Health & Healthcare

How Smart Partnerships Can Help Us Fight Chronic Diseases in Africa
WEF Africa is kicking off today under the theme of “Leadership in an Era of Disruption.” Harald Nusser, Head of Novartis Social Business, emphasizes how novel solutions between the public and the private sector are needed to effectively fight the rising epidemic of chronic diseases in Africa.

Events, Media & Communications

Novartis Dialogue Explores Response to Chronic Illness in Poor Countries

Events, Media & Communications

Novartis Access Shares One-year Learnings and Announces Memorandum of Understanding with Rwanda
Novartis announced today that Rwanda is the third country to sign a memorandum of understanding with Novartis Access after Kenya and Ethiopia. This agreement contributes to the strategy of the Rwandan government to increase investment in prevention, diagnosis and treatment of noncommunicable diseases (NCDs). First Novartis Access product deliveries are expected in early 2017.

Events, Media & Communications

Join the Webcast: Novartis Dialogue to Explore Solutions to the Rise of Chronic Diseases in the Developing World
The event “Improving care for chronic patients in lower-income countries: the patient journey,” will take place November 29, 2016.

Awards, Ratings & Rankings

Novartis Improves Ranking in 2016 Access to Medicine Index
Novartis ranked third in the 2016 Access to Medicine Index (up from 4th place in 2014), in recognition of its efforts to improve worldwide access to healthcare. The Company tops the industry in access-to-medicine management and capacity building.

Health & Healthcare

Time to Talk about Partnerships for Access to Medicines
Access to healthcare is making controversial headlines these days as the report of the High-Level Panel on Access to Medicines set up by the Secretary-General of the United Nations was just released. We need to move away from ideological disputes about intellectual property and focus on how we can help patients receive the treatments they need now.


Any solution to the access challenge needs to consider the complex factors that affect access in developing countries. It would indeed be misleading and counter-productive to focus the access debate on patents.

Health & Healthcare

Kenya Red Cross Society and Novartis Join Forces
The Kenya Red Cross Society (KRCS) has announced a partnership with Novartis to improve access to prevention, treatment, and care of Non Communicable Diseases (NCDs) in Kenya. As part of the new partnership with Novartis, KRCS will train health workers, community volunteers and scale up screening at community and facility level for NCDs over the next three years.
Novartis logo

More from Novartis

  1. Novartis US Foundation commits $25M to improve health equity by reducing health disparities in the US
    Building on $10M+ commitments to date, US Foundation is providing up to an additional $15M due to emergence of COVID-19 pandemic and elevated focus on...

  2. Novartis US Foundation
    Initiatives summarizing efforts from the Novartis US Foundation.

  3. Novartis COVID-19 Trials
    Novartis clinical trial efforts in COVID-19 R&D.

  4. Novartis US Foundation COVID-19 Response
    In response to the COVID-19 pandemic in the US, the Novartis US Foundation established a Response Fund, which will provide USD 5 million over a one...

  5. Novartis – science based innovation for better patient outcomes
    Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.

  6. Novartis Foundation Leprosy Elimination Initiative
    The Novartis Foundation is convening experts from the global health and anti-leprosy community to discuss the current state of leprosy treatment and...

  7. Novartis Access: Medicines to treat chronic diseases in lower-income countries
    Novartis recently announced the launch of the Novartis Access Portfolio, a first-of-its-kind portfolio approach in healthcare industry, aiming to...

  8. The Novartis Malaria Initiative
    For over a decade, the Novartis Malaria Initiative has been a pioneer in the fight against malaria. Focused on access, treatment, R&D and capacity...